Serum Apolipoprotein J in Health, Coronary Heart Disease and Type 2 Diabetes Mellitus

Autor: Masahiro Tsuji, Taro Maruyama, Motoo Tsushima, Satoshi Saito, Mitsuaki Ishihara, Hiroaki Hattori, Yoshiyuki Sasaguri, Takahiro Ueno, Jun Ishii, Irina P. Miller, Tohru Egashira, Takayuki Fujioka, Yoshikazu Miwa, Tadao Iwasaki, Takeshi Kujiraoka, Norman E. Miller
Rok vydání: 2006
Předmět:
Zdroj: Journal of Atherosclerosis and Thrombosis. 13:314-322
ISSN: 1880-3873
1340-3478
Popis: Apolipoprotein (apo) J, clusterin, is ubiquitously expressed in many tissues, and is a component of high-density lipoproteins (HDLs). There is experimental evidence that it may be anti-atherogenic through its effects on cholesterol transport, smooth muscle cell proliferation and lipid peroxidation. HDLs containing apo J and apo A-I carry paraoxonase (PON1), which protects low-density lipoproteins from oxidative modification; however, the extent to which apo J affects coronary heart disease (CHD) is not known. We have developed a sandwich ELISA that enables apo J to be assayed in the range of 13-200 microg/mL. Serum apo J was 52.8+/-0.8 microg/mL (mean+/-SEM; range, 36.0-84.3 microg/mL; n=92) in healthy Japanese men, and 49.3+/-0.5 microg/mL (34.5-72.8; n=241) in healthy Japanese women. Multiple regression of these data and results from 67 men with CHD showed that apo J concentration was unrelated to age, sex or body mass index, but was positively related to serum PON1 (p
Databáze: OpenAIRE